Pfizer says Covid 19 shot teenagers 100% effectively after 4 months

0
14


An Israeli health worker demonstrates bottles of the Pfizer / BioNTech CoVID-19 vaccine for adults (L) and children (R) at the Meuhedet Healthcare Services Organization in Tel Aviv on November 22, 2021. – AFP

WASHINGTON: Pfizer and Biotech said Monday that their COVID-19 vaccine was 100 percent effective in 12- to 15-year-olds four months after the second dose.

The companies said the new data, which included 2,228 trial participants, would help their applications for full approval in the United States and around the world.

People with a follow-up of at least six months after the second dose showed no serious safety concerns.

Albert Borla, CEO of Pfizer, said in a statement: “As the World Health Organization works to increase the number of people vaccinated worldwide, this additional data on the safety and effectiveness profile of our vaccines among young people. Gives more confidence. “

“This is particularly important because we see that in some regions the rate of COVID-19 in this age group is increasing, while vaccine use is declining. We want to share this data with the FDA and other regulators.” Looking forward to

The vaccine was given “emergency use permission” for teens in May, and companies plan to get full approval soon. The vaccine is currently only fully approved in people 16 years of age and older.

Of the 2,228 participants, 30 had confirmed symptomatic COVID cases with no evidence of prior infection, all in the placebo group.

This is equivalent to 100% vaccine efficacy. Efficacy was consistently high in terms of sex, race, obesity level and commodity status.

A major safety concern among this age group is vaccine-associated myocarditis (inflammation of the heart) in men.

But such cases are rare, and statistics show that the benefits of vaccination outweigh the risks. COVID itself can cause myocarditis, both more frequent and more severe.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here